Key result
The aldosterone:renin ratio demonstrated highly significant within-patient reproducibility (r=0.69; P<0.0001) when repeated after an average of 4 weeks in hypertensive patients.
Why the study?
Does the aldosterone:renin ratio (ARR) have good within-patient reproducibility for screening primary aldosteronism in hypertensive patients?
Population
1136 consecutive hypertensive patients referred to specialized centers for hypertension in Italy, with…
Design
Cohort
Follow-up
average 4 weeks
Authors
Loading...
May support ARR reliability for PA screening in hypertension; leaves open prospective validation before changing practice.
Observational (n=1,136)
Yes
Does the aldosterone:renin ratio (ARR) have good within-patient reproducibility for screening primary aldosteronism in hypertensive patients?
Effect estimate: r=0.69
p-value: p=<0.0001
The aldosterone:renin ratio demonstrates good within-patient reproducibility, supporting its use as a reliable screening tool for primary aldosteronism in hypertensive patients.
Rossi et al. (2009) conducted an observational in Hypertension (n=1,136). Aldosterone:Renin Ratio (ARR) was evaluated on Within-patient reproducibility of the ARR (r=0.69, p=<0.0001). The aldosterone:renin ratio demonstrated highly significant within-patient reproducibility (r=0.69; P<0.0001) when repeated after an average of 4 weeks in hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: